Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ...
Zacks.com on MSN9h
FOLD Stock Rises on Settling Galafold Patent Dispute With TevaAmicus also has a second FDA-approved drug in its commercial portfolio. In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component ...
Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s ...
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.
First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement ...
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...
Marshall Wace LLP increased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Free Report) by 56.3% in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback